Relapsed hematologic malignancy
Showing 1 - 25 of 8,407
After Adoptive Transfer of Genetically Modified Cell Products
Recruiting
- Relapsed Hematologic Malignancy
- Refractory Hematologic Malignancy
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Feb 6, 2023
Multiple Myeloma, Relapsed Hematologic Malignancy Trial in Seattle (Digital Health Coaching Program, Fitbit)
Recruiting
- Multiple Myeloma
- Relapsed Hematologic Malignancy
- Digital Health Coaching Program
- Fitbit
-
Seattle, WashingtonUniversity of Washington
Jul 13, 2023
International Leukemia Target Board
Not yet recruiting
- Relapsed Hematologic Malignancy
- Refractory Hematologic Malignancy
- Advice
- (no location specified)
Feb 25, 2022
Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy Trial in United States (Emavusertib, ibrutinib)
Recruiting
- Relapsed Hematologic Malignancy
- Refractory Hematologic Malignancy
-
Phoenix, Arizona
- +10 more
Feb 1, 2023
Relapsed Hematologic Malignancy Trial in Bergamo (donor-derived CIK cells)
Recruiting
- Relapsed Hematologic Malignancy
- donor-derived CIK cells
-
Bergamo, ItalyA O Papa Giovanni XXIII
Dec 22, 2021
Advanced or Metastatic Solid Tumor, Relapsed Hematologic Malignancy Trial in France (IPPACTTO)
Recruiting
- Advanced or Metastatic Solid Tumor
- Relapsed Hematologic Malignancy
- IPPACTTO
-
Angers, France
- +6 more
Apr 21, 2022
CD7+ Acute Leukemia, CD7+ Lymphoma Trial in Hangzhou (anti-CD7 CAR-T)
Recruiting
- CD7+ Acute Leukemia
- CD7+ Lymphoma
- anti-CD7 CAR-T
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital,College of Medicine, Zhejiang Univ
Sep 18, 2022
CB-Long-Term Safety Study (CB-LTSS)
Enrolling by invitation
- Lymphoma, Non-Hodgkin
- +7 more
- Allogeneic CAR-T therapy
-
Irvine, California
- +3 more
Nov 18, 2022
Hematologic Malignancy, Large B-cell Lymphoma, Acute Lymphoblastic Leukemia Trial in Los Angeles (autologous hematopoietic stem
Not yet recruiting
- Hematologic Malignancy
- +5 more
- autologous hematopoietic stem cells added to planned CAR T
-
Los Angeles, CaliforniaCedars-Sinai Medical Center
May 31, 2023
Hematopoietic Malignancy, Relapse/Recurrence, Hematopoietic Stem Cell Transplantation Trial in Suzhou (Umbilical Cord Blood
Recruiting
- Hematopoietic Malignancy
- +2 more
- Umbilical Cord Blood Transplantation
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow university
Nov 6, 2023
Hematological Malignancy Trial in Houston (Fludarabine Phosphate, Cyclophosphamide, CAR.5/IL15-transduced CB-NK cells)
Not yet recruiting
- Hematological Malignancy
- Fludarabine Phosphate
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
Hematological Malignancy, Lymphoma Trial in Canton (SG2501)
Recruiting
- Hematological Malignancy
- Lymphoma
-
Canton, OhioGabrail Cancer Center Research, LLC
Aug 3, 2022
Extended Analysis for Leukemia/Lymphoma Treatment
Completed
- Relapsed Hematologic Malignancy
- ngFDS selected treatment
-
Vienna, AustriaMedical University Vienna
Feb 22, 2021
Hematologic Malignancy, Leukemia, Lymphoma Trial in Boston (CAR-37 T cells)
Recruiting
- Hematologic Malignancy
- +5 more
- CAR-37 T cells
-
Boston, MassachusettsMassachusetts General Hospital Cancer Center
Oct 28, 2021
Solid Tumor, Hematologic Malignancy Trial in Beijing (Eliglustat, Immune checkpoint inhibitor)
Recruiting
- Solid Tumor
- Hematologic Malignancy
- Eliglustat
- Immune checkpoint inhibitor
-
Beijing, ChinaDepartment of Biotherapeutic, Chinese PLA General Hospital
Apr 28, 2022
Hematologic Malignancy Trial in Tianjin (IMM01)
Terminated
- Hematologic Malignancy
-
Tianjin, Tianjin, ChinaChinese Academy of Medical Sciences and Peking Union Medical Col
May 5, 2023
Haematological Malignancy Trial in Parkville (Nivolumab Injection)
Active, not recruiting
- Haematological Malignancy
- Nivolumab Injection
-
Parkville, Victoria, AustraliaRoyal Melbourne Hospital
Sep 21, 2021
Colorectal Cancer, Hematologic Malignancy, Rectum Cancer Trial in Cleveland (Vactosertib, Fludarabine Phosphate,
Recruiting
- Colorectal Cancer
- +11 more
- Vactosertib
- +4 more
-
Cleveland, OhioUniversity Hospitals Cleveland Medical Center, Case Comprehensiv
Jan 18, 2023
Acute Leukemia, Chronic Leukemia, Lymphoma Trial in Milwaukee (Nivolumab (.25 mg/kg), Tocilizumab, Nivolumab (.5 mg/kg))
Terminated
- Acute Leukemia
- +3 more
- Nivolumab (.25 mg/kg)
- +2 more
-
Milwaukee, WisconsinFroedtert Hospital and the Medical College of Wisconsin
Oct 4, 2021
Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Tumor Trial in
Recruiting
- Recurrent Acute Leukemia
- +16 more
- Acetaminophen
- +5 more
-
Duarte, CaliforniaCity of Hope Medical Center
Nov 22, 2022
Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid
Recruiting
- Previously Treated Myelodysplastic Syndrome
- +3 more
- Fludarabine Phosphate
- +9 more
-
Chicago, IllinoisUniversity of Chicago Comprehensive Cancer Center
Jan 7, 2022
Hodgkin's Lymphoma, Lymphoid Leukemia, Lymphoma Trial in Richmond (mycophenolate mofetil, Sargramostim, Filgrastim)
Active, not recruiting
- Hodgkin's Lymphoma
- +17 more
- mycophenolate mofetil
- +2 more
-
Richmond, VirginiaVirginia Commonwealth University/Massey Cancer Center
Dec 21, 2021
Hematologic Malignancy, Acute Myeloid Leukemia, MDS Trial in Chengdu, Shenzhen (CLL1-CD33 cCAR T cells)
Recruiting
- Hematologic Malignancy
- +4 more
- CLL1-CD33 cCAR T cells
-
Chengdu, China
- +1 more
May 17, 2021